The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 10, 2014
Filed:
May. 10, 2012
Eugene T. Michal, San Francisco, CA (US);
Evgenia Mandrusov, Campbell, CA (US);
Charles D. Claude, Santa Clara, CA (US);
NI Ding, San Jose, CA (US);
Murthy Simhambhatla, San Jose, CA (US);
Syed Faiyez Ahmed Hossainy, Fremont, CA (US);
Srinivasan Sridharan, Morgan Hill, CA (US);
Paul Consigny, San Jose, CA (US);
Eugene T. Michal, San Francisco, CA (US);
Evgenia Mandrusov, Campbell, CA (US);
Charles D. Claude, Santa Clara, CA (US);
Ni Ding, San Jose, CA (US);
Murthy Simhambhatla, San Jose, CA (US);
Syed Faiyez Ahmed Hossainy, Fremont, CA (US);
Srinivasan Sridharan, Morgan Hill, CA (US);
Paul Consigny, San Jose, CA (US);
Abbott Cardiovascular Systems Inc., Santa Clara, CA (US);
Abstract
Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.